299 related articles for article (PubMed ID: 28077020)
1. Relationship between
Hammers DB; Atkinson TJ; Dalley BC; Suhrie KR; Beardmore BE; Burrell LD; Horn KP; Rasmussen KM; Foster NL; Duff K; Hoffman JM
Clin Neuropsychol; 2017 Apr; 31(3):531-543. PubMed ID: 28077020
[TBL] [Abstract][Full Text] [Related]
2. Amyloid Positivity Using [18F]Flutemetamol-PET and Cognitive Deficits in Nondemented Community-Dwelling Older Adults.
Hammers DB; Atkinson TJ; Dalley BCA; Suhrie KR; Horn KP; Rasmussen KM; Beardmore BE; Burrell LD; Duff K; Hoffman JM
Am J Alzheimers Dis Other Demen; 2017 Sep; 32(6):320-328. PubMed ID: 28403622
[TBL] [Abstract][Full Text] [Related]
3. Amyloid deposition and cognition in older adults: the effects of premorbid intellect.
Duff K; Foster NL; Dennett K; Hammers DB; Zollinger LV; Christian PE; Butterfield RI; Beardmore BE; Wang AY; Morton KA; Hoffman JM
Arch Clin Neuropsychol; 2013 Nov; 28(7):665-71. PubMed ID: 23817438
[TBL] [Abstract][Full Text] [Related]
4. 18F PET with flutemetamol for the early diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI).
Martínez G; Vernooij RW; Fuentes Padilla P; Zamora J; Flicker L; Bonfill Cosp X
Cochrane Database Syst Rev; 2017 Nov; 11(11):CD012884. PubMed ID: 29164602
[TBL] [Abstract][Full Text] [Related]
5. Clinical impact of [
Leuzy A; Savitcheva I; Chiotis K; Lilja J; Andersen P; Bogdanovic N; Jelic V; Nordberg A
Eur J Nucl Med Mol Imaging; 2019 Jun; 46(6):1276-1286. PubMed ID: 30915522
[TBL] [Abstract][Full Text] [Related]
6. Effect of amyloid on memory and non-memory decline from preclinical to clinical Alzheimer's disease.
Lim YY; Maruff P; Pietrzak RH; Ames D; Ellis KA; Harrington K; Lautenschlager NT; Szoeke C; Martins RN; Masters CL; Villemagne VL; Rowe CC;
Brain; 2014 Jan; 137(Pt 1):221-31. PubMed ID: 24176981
[TBL] [Abstract][Full Text] [Related]
7. Predicting biomarkers in intact older adults and those with amnestic Mild Cognitive Impairment, and mild Alzheimer's Disease using the Repeatable Battery for the Assessment of Neuropsychological Status.
Suhrie KR; Hammers DB; Porter SM; Dixon AM; King JB; Anderson JS; Duff K; Hoffman JM
J Clin Exp Neuropsychol; 2021 Nov; 43(9):861-878. PubMed ID: 35019815
[TBL] [Abstract][Full Text] [Related]
8. Associations between tau, Aβ, and cortical thickness with cognition in Alzheimer disease.
Ossenkoppele R; Smith R; Ohlsson T; Strandberg O; Mattsson N; Insel PS; Palmqvist S; Hansson O
Neurology; 2019 Feb; 92(6):e601-e612. PubMed ID: 30626656
[TBL] [Abstract][Full Text] [Related]
9. Relationships between flortaucipir PET tau binding and amyloid burden, clinical diagnosis, age and cognition.
Pontecorvo MJ; Devous MD; Navitsky M; Lu M; Salloway S; Schaerf FW; Jennings D; Arora AK; McGeehan A; Lim NC; Xiong H; Joshi AD; Siderowf A; Mintun MA;
Brain; 2017 Mar; 140(3):748-763. PubMed ID: 28077397
[TBL] [Abstract][Full Text] [Related]
10. Use of Flutemetamol F 18-Labeled Positron Emission Tomography and Other Biomarkers to Assess Risk of Clinical Progression in Patients With Amnestic Mild Cognitive Impairment.
Wolk DA; Sadowsky C; Safirstein B; Rinne JO; Duara R; Perry R; Agronin M; Gamez J; Shi J; Ivanoiu A; Minthon L; Walker Z; Hasselbalch S; Holmes C; Sabbagh M; Albert M; Fleisher A; Loughlin P; Triau E; Frey K; Høgh P; Bozoki A; Bullock R; Salmon E; Farrar G; Buckley CJ; Zanette M; Sherwin PF; Cherubini A; Inglis F
JAMA Neurol; 2018 Sep; 75(9):1114-1123. PubMed ID: 29799984
[TBL] [Abstract][Full Text] [Related]
11. Repeatable battery for the assessment of neuropsychological status and its relationship to biomarkers of Alzheimer's disease.
Duff K; Suhrie KR; Hammers DB; Dixon AM; King JB; Koppelmans V; Hoffman JM
Clin Neuropsychol; 2023 Jan; 37(1):157-173. PubMed ID: 34713772
[TBL] [Abstract][Full Text] [Related]
12. Change on the Repeatable Battery for the Assessment of Neuropsychological Status and its relationship to brain amyloid.
Duff K; Dixon AM; Embree L; Hoffman JM
J Clin Exp Neuropsychol; 2023 Mar; 45(2):105-117. PubMed ID: 37224404
[TBL] [Abstract][Full Text] [Related]
13. [(18)F]flutemetamol amyloid positron emission tomography in preclinical and symptomatic Alzheimer's disease: specific detection of advanced phases of amyloid-β pathology.
Thal DR; Beach TG; Zanette M; Heurling K; Chakrabarty A; Ismail A; Smith AP; Buckley C
Alzheimers Dement; 2015 Aug; 11(8):975-85. PubMed ID: 26141264
[TBL] [Abstract][Full Text] [Related]
14. Regional dynamics of amyloid-β deposition in healthy elderly, mild cognitive impairment and Alzheimer's disease: a voxelwise PiB-PET longitudinal study.
Villain N; Chételat G; Grassiot B; Bourgeat P; Jones G; Ellis KA; Ames D; Martins RN; Eustache F; Salvado O; Masters CL; Rowe CC; Villemagne VL;
Brain; 2012 Jul; 135(Pt 7):2126-39. PubMed ID: 22628162
[TBL] [Abstract][Full Text] [Related]
15. Comparison of qualitative and quantitative imaging characteristics of [11C]PiB and [18F]flutemetamol in normal control and Alzheimer's subjects.
Mountz JM; Laymon CM; Cohen AD; Zhang Z; Price JC; Boudhar S; McDade E; Aizenstein HJ; Klunk WE; Mathis CA
Neuroimage Clin; 2015; 9():592-8. PubMed ID: 26640770
[TBL] [Abstract][Full Text] [Related]
16. Imaging β-amyloid using [(18)F]flutemetamol positron emission tomography: from dosimetry to clinical diagnosis.
Heurling K; Leuzy A; Zimmer ER; Lubberink M; Nordberg A
Eur J Nucl Med Mol Imaging; 2016 Feb; 43(2):362-373. PubMed ID: 26440450
[TBL] [Abstract][Full Text] [Related]
17. Post-mortem histopathology underlying β-amyloid PET imaging following flutemetamol F 18 injection.
Ikonomovic MD; Buckley CJ; Heurling K; Sherwin P; Jones PA; Zanette M; Mathis CA; Klunk WE; Chakrabarty A; Ironside J; Ismail A; Smith C; Thal DR; Beach TG; Farrar G; Smith AP
Acta Neuropathol Commun; 2016 Dec; 4(1):130. PubMed ID: 27955679
[TBL] [Abstract][Full Text] [Related]
18. The EMIF-AD PreclinAD study: study design and baseline cohort overview.
Konijnenberg E; Carter SF; Ten Kate M; den Braber A; Tomassen J; Amadi C; Wesselman L; Nguyen HT; van de Kreeke JA; Yaqub M; Demuru M; Mulder SD; Hillebrand A; Bouwman FH; Teunissen CE; Serné EH; Moll AC; Verbraak FD; Hinz R; Pendleton N; Lammertsma AA; van Berckel BNM; Barkhof F; Boomsma DI; Scheltens P; Herholz K; Visser PJ
Alzheimers Res Ther; 2018 Aug; 10(1):75. PubMed ID: 30075734
[TBL] [Abstract][Full Text] [Related]
19. Simultaneous quantitative susceptibility mapping and Flutemetamol-PET suggests local correlation of iron and β-amyloid as an indicator of cognitive performance at high age.
van Bergen JMG; Li X; Quevenco FC; Gietl AF; Treyer V; Meyer R; Buck A; Kaufmann PA; Nitsch RM; van Zijl PCM; Hock C; Unschuld PG
Neuroimage; 2018 Jul; 174():308-316. PubMed ID: 29548847
[TBL] [Abstract][Full Text] [Related]
20. Is there a difference in regional read [
Farrar G; Molinuevo JL; Zanette M
Eur J Nucl Med Mol Imaging; 2019 Jun; 46(6):1299-1308. PubMed ID: 30863934
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
